RenovoRx in $10m–$20m Series C fundraising mode for Phase III pancreatic cancer trial, CEO says

RenovoRx investor pitches for $10–$20m Series C
In terms of the ongoing fundraising round, California-based RenovoRx is already speaking with investors and US banks. Credit: NIH Image Gallery.